The failure of ALS phase III research made the $250 million acquisition between trophos and actelion fail

Source: trophos, France, Dec 15, 2011, compiled by China Council for the promotion of drugs, said that the drug (olesoxi) for ALS (amyotrophic lateral sclerosis) failed to reach the main end point in phase III clinical research, which will cause investors to lose 250 million US dollars This is the maximum amount actelion has committed to pay trophos, and actelion has paid 10 million euros for the purchase right Trophos recruited 512 ALS patients for this study, but it should be noted that the survival rate of patients in the olesoxic group did not improve compared with that in the riluzole / placebo group Biotech quickly concluded that the failure of the phase III study may be due to poor health after diagnosis "In the most widely used ALS model, motor neurons and neuromuscular connections lost more than 50% compared with the first symptoms," the developer said in a statement Trophos believes this is a problem that is unlikely to be encountered in independent trial drug studies in patients with multiple sclerosis That's not enough for actelion, a Swiss biotech company that has run short of money, signed the purchase option for ollisossi in the summer of 2010 Actelion, which needs new products and a winning product line, immediately renounced its purchase rights Analysts point out that late development is a high-risk game, and the current trend is to end unfulfilled agreements as soon as possible rather than delay Trophos is now starting several other clinical projects "We still believe in the future of our cholesterol oxime, mitochondrial pore regulatory compounds," said Damian Malone, chief executive of trophos "We have to ensure that trophos's funding is available at least through the end of 2013 in order to continue to advance our other pilot programs to address rare diseases or specific indications without treatment that have large medical needs."